Eton Pharmaceuticals, Inc. Research and Development Expense
Eton Pharmaceuticals, Inc. (ETON) reported Research and Development Expense of $993.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $993.00K, a 73.25% decline year-over-year.
- Eton Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $1.88M, a 61.50% increase year-over-year.
- Eton Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $1.78M.
- Eton Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $1.11M, a 120.20% increase year-over-year.
- Eton Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $7.76M, a 138.56% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $3.25M, a 2.02% decline from fiscal 2023.
- Eton Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $3.32M, a 16.87% decline from fiscal 2022.
- Eton Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $4.00M, a 35.91% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 5 month | Research and Development Expense 6 month | Research and Development Expense 8 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $993.00K 10-Q · filed 2026-08-13 | $2.87M 10-Q · filed 2026-08-13 | $4.65M derived: sum of 3 quarters · filed 2026-08-13 | $5.76M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $1.88M 10-Q · filed 2026-05-14 | $3.65M derived: sum of 2 quarters · filed 2026-05-14 | $4.77M derived: sum of 3 quarters · filed 2026-05-14 | $8.48M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.89M derived: sum of 2 quarters · filed 2026-03-19 | $6.60M derived: sum of 3 quarters · filed 2026-08-13 | $7.76M 10-K · filed 2026-03-19 | ||
| 2025-09-30 | $1.11M 10-Q · filed 2025-11-06 | $4.82M derived: sum of 2 quarters · filed 2026-08-13 | $5.99M 10-Q · filed 2025-11-06 | $5.11M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $3.71M 10-Q · filed 2026-08-13 | $4.87M 10-Q · filed 2026-08-13 | $4.00M derived: sum of 3 quarters · filed 2026-08-13 | $4.51M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $1.16M 10-Q · filed 2026-05-14 | $290.00K derived: sum of 2 quarters · filed 2026-05-14 | $795.00K derived: sum of 3 quarters · filed 2026-05-14 | $3.77M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$871.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$366.00K derived: sum of 2 quarters · filed 2026-03-19 | $2.60M derived: sum of 3 quarters · filed 2026-03-19 | $3.25M 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $505.00K 10-Q · filed 2025-11-06 | $3.48M derived: sum of 2 quarters · filed 2025-11-06 | $4.13M 10-Q · filed 2025-11-06 | $5.17M derived: sum of 4 quarters · filed 2026-03-19 | ||
| 2024-06-30 | $2.97M 10-Q · filed 2025-08-07 | $3.62M 10-Q · filed 2025-08-07 | $4.67M derived: sum of 3 quarters · filed 2026-03-19 | $5.28M derived: sum of 4 quarters · filed 2026-03-19 | ||
| 2024-03-31 | $651.00K 10-Q · filed 2025-05-13 | $1.70M derived: sum of 2 quarters · filed 2026-03-19 | $2.31M derived: sum of 3 quarters · filed 2026-03-19 | $3.44M derived: sum of 4 quarters · filed 2026-03-19 | ||
| 2023-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.66M derived: sum of 2 quarters · filed 2026-03-19 | $2.79M derived: sum of 3 quarters · filed 2026-03-19 | $3.32M 10-K · filed 2026-03-19 | ||
| 2023-09-30 | $615.00K 10-Q · filed 2024-11-12 | $1.74M derived: sum of 2 quarters · filed 2024-11-12 | $2.27M 10-Q · filed 2024-11-12 | $3.22M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-06-30 | $1.13M 10-Q · filed 2024-08-08 | $1.66M 10-Q · filed 2024-08-08 | $2.60M derived: sum of 3 quarters · filed 2025-03-18 | $3.35M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-03-31 | $535.00K 10-Q · filed 2024-05-09 | $1.48M derived: sum of 2 quarters · filed 2025-03-18 | $2.22M derived: sum of 3 quarters · filed 2025-03-18 | $2.91M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2022-12-31 | $944.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.69M derived: sum of 2 quarters · filed 2025-03-18 | $2.38M derived: sum of 3 quarters · filed 2025-03-18 | $4.00M 10-K · filed 2025-03-18 | ||
| 2022-09-30 | $744.00K 10-Q · filed 2023-11-09 | $1.43M derived: sum of 2 quarters · filed 2023-11-09 | $3.05M 10-Q · filed 2023-11-09 | $3.73M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $690.00K 10-Q · filed 2023-08-10 | $2.31M 10-Q · filed 2023-08-10 | $2.99M derived: sum of 3 quarters · filed 2024-03-14 | $5.67M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | $1.62M 10-Q · filed 2023-05-11 | $2.30M derived: sum of 2 quarters · filed 2024-03-14 | $4.98M derived: sum of 3 quarters · filed 2024-03-14 | $6.97M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-12-31 | $681.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.36M derived: sum of 2 quarters · filed 2024-03-14 | $5.35M derived: sum of 3 quarters · filed 2024-03-14 | $6.24M 10-K · filed 2024-03-14 | ||
| 2021-09-30 | $2.68M 10-Q · filed 2022-11-10 | $4.67M derived: sum of 2 quarters · filed 2022-11-10 | $5.55M 10-Q · filed 2022-11-10 | $8.96M derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2021-06-30 | $1.99M 10-Q · filed 2022-08-11 | $2.88M 10-Q · filed 2022-08-11 | $6.28M derived: sum of 3 quarters · filed 2023-03-16 | $9.10M derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2021-03-31 | $886.00K 10-Q · filed 2022-05-12 | $4.29M derived: sum of 2 quarters · filed 2023-03-16 | $7.11M derived: sum of 3 quarters · filed 2023-03-16 | $8.72M derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2020-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $6.23M derived: sum of 2 quarters · filed 2023-03-16 | $7.84M derived: sum of 3 quarters · filed 2023-03-16 | $14.10M 10-K · filed 2023-03-16 | ||
| 2020-09-30 | $2.83M 10-Q · filed 2021-11-16 | $4.43M derived: sum of 2 quarters · filed 2021-11-16 | $10.70M 10-Q · filed 2021-11-16 | $10.94M derived: sum of 4 quarters · filed 2022-03-16 | ||
| 2020-06-30 | $1.61M 10-Q · filed 2021-08-16 | $7.88M 10-Q · filed 2021-08-16 | $8.11M derived: sum of 3 quarters · filed 2022-03-16 | $11.53M derived: sum of 4 quarters · filed 2022-03-16 | ||
| 2020-03-31 | $6.27M 10-Q · filed 2021-05-13 | $6.50M derived: sum of 2 quarters · filed 2022-03-16 | $9.92M derived: sum of 3 quarters · filed 2022-03-16 | $11.36M derived: sum of 4 quarters · filed 2022-03-16 | ||
| 2019-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $3.65M derived: sum of 2 quarters · filed 2022-03-16 | $5.09M derived: sum of 3 quarters · filed 2022-03-16 | $11.55M 10-K · filed 2022-03-16 | ||
| 2019-09-30 | $3.42M 10-Q · filed 2020-11-12 | $4.86M derived: sum of 2 quarters · filed 2020-11-12 | $11.32M 10-Q · filed 2020-11-12 | $12.42M derived: sum of 4 quarters · filed 2021-03-16 | ||
| 2019-06-30 | $1.44M 10-Q · filed 2020-08-12 | $7.90M 10-Q · filed 2020-08-12 | $9.01M derived: sum of 3 quarters · filed 2021-03-16 | $10.55M derived: sum of 4 quarters · filed 2021-03-16 | ||
| 2019-03-31 | $6.46M 10-Q · filed 2020-05-14 | $7.57M derived: sum of 2 quarters · filed 2021-03-16 | $9.11M derived: sum of 3 quarters · filed 2021-03-16 | $10.82M derived: sum of 4 quarters · filed 2021-03-16 | ||
| 2018-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $2.65M derived: sum of 2 quarters · filed 2021-03-16 | $4.35M derived: sum of 3 quarters · filed 2021-03-16 | $5.63M 10-K · filed 2021-03-16 | ||
| 2018-09-30 | $1.54M 10-Q · filed 2019-11-14 | $3.25M derived: sum of 2 quarters · filed 2019-11-14 | $4.53M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $1.71M 10-Q · filed 2019-08-06 | $2.98M 10-Q · filed 2019-08-06 | ||||
| 2018-03-31 | $1.27M 10-Q · filed 2019-05-07 | |||||
| 2017-12-31 | $3.93M 10-K · filed 2020-03-05 | |||||
| 2017-09-30 | $1.56M 10-Q · filed 2018-12-20 | $3.07M 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |